.Pharmacolibrary.Drugs.ATC.D.D03AX16 .Pharmacolibrary.Drugs.ATC.D.D03AX16| name: | BeremageneGeperpavec |
| ATC code: | D03AX16 | route: | topical |
| n-compartments | 1 |
Beremagene geperpavec is a topical gene therapy consisting of a modified herpes-simplex virus type 1 vector encoding the human COL7A1 gene. It is indicated for the treatment of dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder characterized by defects in type VII collagen. Beremagene geperpavec restores COL7A1 gene expression and facilitates production of functional type VII collagen at the dermal-epidermal junction. The drug received FDA approval in 2023 for use in patients with DEB.
No published pharmacokinetic data are available for beremagene geperpavec in humans. Due to its design as a non-replicating topical gene therapy, systemic absorption is expected to be minimal or absent. No specific data available for individuals by sex, age, or condition.